Rescue clinical trials, specifically those that have delayed initial start date, often need rescuing for many reasons, such as resources becoming scarce and the impact of the Covid-19 pandemic. GlobalData’s Pharmaceutical Intelligence Centre has compiled data on rescue trials, noticing a trend in delayed initial trial start dates.
Trials with delayed initial start dates have increased steadily since 2016, with the most being this year with 5,578. Looking by therapy area, oncology had the most clinical trials in that period with 7,753 trials, followed by the central nervous system and infectious diseases to round out the top three. But when looking at percentage increases over the past five years, infectious disease was the highest at 198%, followed by the central nervous system at 123% and musculoskeletal disorders at 106%. Oncology had the fourth highest percentage increase with 98%. Lastly, the number of trials with a delayed start date for infectious disease doubled between 2019 and last year. This may be due to companies focusing on vaccines and therapeutics for Covid-19. A further breakdown can be seen in Figure 1.
As trends show, the number of trials with delayed initial start dates will continue to rise. This may be due to the rising number of Covid-19 cases due to its variants, which will create more obstacles for companies to overcome.